Founding rationale

“ In a recent decade or two, many preclinical and clinical studies showed that ribosomes and mRNA translation into proteins are either directly or indirectly involved as a driver or as a manifestation of many diseases. The range of diseases include cancers to metastatic cancers, neurodevelopmental to neurodegenerative disorders and rare to the rarest of the diseases.

We founded TranslaTale in October-2022 with an aim of targeting this crux in biology, the ribosome and ultimately the mRNA translation, to cure diseases and tell a story through our science. ”

Our science

Protein expression is tightly regulated and rate limited by ribosomes and their job of translating mRNA into protein, which act as the crux for gene expression into proteins.

However, current drug discovery pipelines are oblivious to the effects of diseases and drugs on these crucial processes in protein synthesis.

A wide range of diseases are caused by deregulation in ribosome and mRNA translation. However, there aren't enough platforms to rapidly detect the effect of drugs on on this crux.

We are building biological platforms using a combination of experimental and data techniques to address this issue. This will enable discovery of novel drugs for difficult to treat diseases.